Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection

This study has been completed.
Sponsor:
Collaborators:
Acute Infection and Early Disease Research Program
AIDS Clinical Trials Group
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00183261
First received: September 13, 2005
Last updated: June 7, 2013
Last verified: June 2013

September 13, 2005
June 7, 2013
March 2006
August 2007   (final data collection date for primary outcome measure)
  • Average of log10 HIV-1 RNA viral load [ Time Frame: At Weeks 58 and 63 ] [ Designated as safety issue: No ]
  • Frequency of Grade 3 or 4 systemic adverse events, the occurrence of a severe or life-threatening injection site adverse event, or death [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]
  • Average of log10 HIV-1 RNA viral load at Weeks 58 and 63
  • frequency of Grade 3 or 4 systemic adverse events, the occurrence of a severe or life-threatening injection site adverse event, or death from time of vaccination until Week 63
Complete list of historical versions of study NCT00183261 on ClinicalTrials.gov Archive Site
  • Distribution of plasma HIV RNA viral load [ Time Frame: At Weeks 63 and 87 ] [ Designated as safety issue: No ]
  • Proportion of patients with controlled viremia and their respective distribution of plasma HIV RNA viral load [ Time Frame: At Weeks 63 and 87 ] [ Designated as safety issue: No ]
  • Mean viral burden, defined as time-averaged area under the log10 HIV-1 RNA viral load curve [ Time Frame: At Weeks 63 and 87 ] [ Designated as safety issue: No ]
  • HIV DNA levels [ Time Frame: At Weeks 30, 38, 63, and 87 ] [ Designated as safety issue: No ]
  • HIV-1 DNA levels [ Time Frame: At Weeks 30, 38, 46, 50, 63, and 87 ] [ Designated as safety issue: No ]
  • Magnitude and absolute change in CD4 and CD8 counts [ Time Frame: At Weeks 63 and 87 ] [ Designated as safety issue: No ]
  • Percent and absolute change in the number of HIV-1- specific CD8 cells, as measured by interferon (IFN)-gamma Elispot assay and intracellular cytokine staining [ Time Frame: Through Week 30 ] [ Designated as safety issue: No ]
  • Percent and absolute change in the cytokine secretion patterns and the proliferative capacity of HIV-1- specific CD4 and CD8 cells, as measured by multiparameter flow cytometry [ Time Frame: Through Week 30 ] [ Designated as safety issue: No ]
  • Breadth and magnitude of HIV-1- specific CD4 and CD8 cell responses [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • Time to reach the specified virologic or immunologic criteria for reinitiating antiretroviral therapy after treatment interruption [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • Frequency of Grade 3 or 4 systemic adverse events or the occurrence of a severe or life-threatening injection site adverse event, or HIV-related events, AIDS-defining infections, and death from time of vaccination [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]
  • Cell-associated infectivity in latently infected cells [ Time Frame: At Week 63 ] [ Designated as safety issue: No ]
  • Cell-associated infectivity at Week 63 and immunologic responses [ Time Frame: At Weeks 63 and 87 ] [ Designated as safety issue: No ]
  • Median plasma HIV RNA viral load at Weeks 63 and 87
  • proportion of patients with controlled viremia and their respective median plasma HIV RNA viral load at Weeks 63 and 87
  • mean viral burden, defined as time-averaged area under the log10 HIV-1 RNA viral load curve at Weeks 63 and 87
  • HIV DNA levels at Weeks 30, 38, 63, and 87
  • HIV-1 DNA levels at Weeks 30, 38, 46, 50, 63, and 87
  • magnitude and absolute change in CD4 and CD8 counts at Weeks 63 and 87
  • percent and absolute change in the number of HIV-1 specific CD8 cells, as measured by interferon (IFN)-gamma Elispot assay and intracellular cytokine staining, from baseline to Week 30
  • percent and absolute change in the cytokine secretion patterns and the proliferative capacity of HIV-1 specific CD4 and CD8 cells, as measured by multiparameter flow cytometry from baseline to Week 30
  • breadth and magnitude of HIV-1 specific CD4 and CD8 cell responses at Week 38 and time to reaching the specified virologic or immunologic criteria for reinitiating antiretroviral therapy after treatment interruption
  • time to reach the specified virologic or immunologic criteria for reinitiating antiretroviral therapy after treatment interruption
  • frequency of Grade 3 or 4 systemic adverse events or the occurrence of a severe or life-threatening injection site adverse event until Week 240, or HIV-related events, AIDS-defining infections, and death from time of vaccination until Week 87
  • cell-associated infectivity in latently infected cells at Week 63
  • cell-associated infectivity at Week 63 and immunologic responses at Weeks 63 and 87
Not Provided
Not Provided
 
Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection
A Randomized Phase II Study of Therapeutic Immunization and Treatment Interruption Among Subjects Who Began Potent Antiretroviral Therapy Within 30 Days of Diagnosis of Acute or Recent HIV Infection

The purpose of this study is to determine whether the HIV vaccine MRKAd5 HIV-1 gag/pol/nef followed by treatment interruption can increase immune system function in adults with acute or recent HIV infection who have started taking anti-HIV drugs.

While the advent of highly active antiretroviral therapy (HAART) has contributed to the increasing control of HIV infection and viral replication, ultimate control of HIV infection will require the development of effective HIV-specific immunity in HIV infected individuals. Therapeutic vaccination within the earliest weeks following acute or recent HIV infection may increase the immune system's response to HIV. This study will determine whether MRKAd5 HIV-1 gag/pol/nef vaccine followed by treatment interruption can maintain viral suppression in patients with acute or recent HIV infection.

The interventional part of the study will last 102 weeks. Participants will be randomly assigned to receive either MRKAd5 HIV-1 gag/pol/nef or placebo vaccine at baseline and Weeks 4 and 26. Participants must remain on HAART from study entry until Week 38. Participants whose HIV viral load rebounds two times or more above 500 copies/ml by Weeks 39 to 41 will not enter Step 2 of the study. Participants whose viral load drops to 500 copies/ml or less by Weeks 39 to 41 will enter Step 2, where they will discontinue HAART for 24 weeks. Participants in Step 2 will have plasma HIV viral loads measured every 2 weeks for the first 4 weeks and weekly for the next 3 weeks. Study participants will continue in Step 2 until they experience virologic and immunologic failure or they need to restart HAART for another reason; they will then enter Step 3, where they will reinitiate HAART. Step 3 participants will continue on HAART until Week 102. A long-term safety follow-up period will occur from Weeks 103 to 240.

Timing of the study visits will be determined by which steps a participant enters. A physical exam and blood and urine collection will occur at most study visits throughout the study until Week 102. Follow-up phone calls to study participants will occur every 6 months from Week 102 until Week 240 to collect long-term safety data, including clinical status, CD4 count, and medication history. During the long-term safety follow-up, participants will also have study visits every 6 months. Visits will include medical and medication history.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Treatment
HIV Infections
  • Biological: MRKAd5 HIV-1 gag/pol/nef
    1.5 x 1010 Ad vg/mL, 1.0 mL administered intramuscularly
  • Biological: MRKAd5 HIV-1 gag/pol/nef placebo
    1.0 mL administered intramuscularly
  • Experimental: 1
    Participants will receive the MRKAd5 HIV-1 gag/pol/nef vaccine at study entry and on Weeks 4 and 26
    Intervention: Biological: MRKAd5 HIV-1 gag/pol/nef
  • Placebo Comparator: 2
    Participants will receive the MRKAd5 HIV-1 gag/pol/nef vaccine placebo at study entry and on Weeks 4 and 26
    Intervention: Biological: MRKAd5 HIV-1 gag/pol/nef placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
October 2010
August 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Initiated HAART within 30 days of an acute or recent HIV-1 infection diagnosis. More information on this criterion can be found in the protocol.
  • Initiated HAART within 30 days of documented acute or recent HIV-1 infection without interruption for more than 7 days
  • Sustained viral suppression, defined as a viral load of 500 copies/mL or less 12 months prior to baseline with an undetectable HIV-1 RNA viral load between 60 to 7 days prior to baseline
  • CD4 count of 450 cells/mm3 or more OR 35% or more between 60 to 14 days prior to baseline
  • Ad5 neutralizing antibody titer of 200 or less at screening
  • Willing to follow all study procedures and schedules
  • Willing to interrupt HAART for at least 24 weeks following completion of the vaccination stage
  • Negative for hepatitis B surface antigen (HBsAg) at screening
  • Willing to use acceptable forms of contraception
  • Infected with HIV-1 subtype B, if this information is available

Exclusion Criteria:

  • Virologic relapse, defined as 2 consecutive measurements of viral load of 500 copies/mL or more at least 7 days apart within 12 months of baseline visit
  • Received more than 7 days of continuous HAART other than that received within 16 days of acute or recent HIV-1 infection. Participants who received HAART as part of post-exposure prophylaxis (PEP) more than 6 months prior to the start of initial HAART may be eligible, provided that they did not acquire HIV-1 infection from the event that required PEP.
  • History of anaphylaxis or allergy to vaccine components, including Tris buffer, magnesium chloride, and polysorbate 80 (Tween)
  • History of clinically significant heart, lung, kidney, liver, pancreatic, gastrointestinal, or neurological disease that, in the opinion of the study investigator, may interfere with the study
  • Contraindication to intramuscular (IM) injection, such as anticoagulant therapy or thrombocytopenia
  • Receipt of any immune globulin or blood products within 3 months prior to baseline
  • Receipt of any live vaccine within 30 days prior to baseline or any inactivated vaccine within 14 days prior to baseline
  • Previous receipt of any HIV vaccine. Participants that were documented to have received only placebo are not excluded.
  • History of any AIDS-defining illness. If a participant's sole AIDS-defining illness is Kaposi's sarcoma limited to the skin and is not anticipated to require systemic chemotherapy, that participant is not excluded.
  • Currently receiving drugs or biologics not approved by the Food and Drug Administration (FDA) other than investigational HIV medications
  • Current or past participation in other studies that might alter the participant's response to the study vaccination
  • Use of any immunomodulatory agents, including but not limited to interleukin-2 (IL-2), granulocyte/macrophage-colony stimulating factor (GM-CSF), and systemic corticosteroids, within 30 days prior to baseline
  • Active alcohol or substance use that, in the investigator's opinion, may interfere with the study
  • Any other criteria or condition that, in the investigator's opinion, may interfere with the study
  • Unwilling or unable to contribute to the planned peripheral blood mononuclear cell (PBMC) blood collection
  • Pregnancy or breastfeeding
Both
18 Years to 55 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   American Samoa,   Australia
 
NCT00183261
AIN504/A5218, 10025, AIN504/ACTG A5218, AIN504-A5218
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
  • Acute Infection and Early Disease Research Program
  • AIDS Clinical Trials Group
Study Chair: Susan Little, MD University of California, San Diego AIDS Vaccine Research Center
Study Chair: Douglas D. Richman, MD Departments of Pathology and Medicine, University of California, San Diego
National Institute of Allergy and Infectious Diseases (NIAID)
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP